UMIN ID: UMIN000054141
Registered date:13/04/2024
Clinical Study on Additional Treatment of Hyperuricemia with Dotinurad
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Hyperuricemic patients with uric acid level of 7.0 mg/dL or higher while taking febuxostat |
Date of first enrollment | 2024/03/16 |
Target sample size | 20 |
Countries of recruitment | Japan |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | uric acid |
---|---|
Secondary Outcome | 1) BUN, Cr, eGFR 2) Cystatin C 3) Oxidized LDL, high sensitivity CRP 4) Albuminuria 5) Side effects |
Key inclusion & exclusion criteria
Age minimum | 20years-old |
---|---|
Age maximum | 90years-old |
Gender | Male and Female |
Include criteria | |
Exclude criteria | Patients who were deemed not appropriate to participate in this study by doctor |
Related Information
Primary Sponsor | Sekino Hospital |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | self funding |
Secondary ID(s) |
Contact
public contact | |
Name | Mitsue Akiyama |
Address | 3-28-3 Ikebukuro, Toshima-ku, Tokyo, Japan Japan 1710014 |
Telephone | 03-3986-5501 |
skn-np@sekino-hospital.com | |
Affiliation | Sekino Laboratory Department of Research |
scientific contact | |
Name | Akira Sezai |
Address | 30-1 Oyaguchi kami-machi, Itabashi-ku, Tokyo, Japan Japan |
Telephone | 03-3972-8111 |
asezai.med@gmail.com | |
Affiliation | Nihon University School of Medicine Department of Cardiovascular Surgery |